Metformin-induced reductions in tumor growth involves modulation of the gut microbiome

• Main Authors: Lindsay A. Broadfield (Author), Amna Saigal (Author), Jake C. Szamosi (Author), Joanne A. Hammill (Author), Ksenia Bezverbnaya (Author), Dongdong Wang (Author), Jaya Gautam (Author), Evangelia E. Tsakiridis (Author), Fiorella Di Pastena (Author), Jamie McNicol (Author), Jianhan Wu (Author), Saad Syed (Author), James S.V. Lally (Author), Amogelang R. Raphenya (Author), Marie-Jose Blouin (Author), Michael Pollak (Author), Andrea Sacconi (Author), Giovanni Blandino (Author), Andrew G. McArthur (Author), Jonathan D. Schertzer (Author), Michael G. Surette (Author), Stephen M. Collins (Author), Jonathan L. Bramson (Author), Paola Muti (Author), Theodoros Tsakiridis (Author), Gregory R. Steinberg (Author)
• Format: Book
• Published: Elsevier, 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background/Purpose: Type 2 diabetes and obesity increase the risk of developing colorectal cancer. Metformin may reduce colorectal cancer but the mechanisms mediating this effect remain unclear. In mice and humans, a high-fat diet (HFD), obesity and metformin are known to alter the gut microbiome bu...